Department of Molecular, Cell and Cancer Biology
Bacterial Infections and Mycoses | Cell Biology | Immunoprophylaxis and Therapy | Immunotherapy | Infectious Disease | Microbiology | Virus Diseases
SARS-CoV-2-infected patients are reported to show immunocompromised behavior that gives rise to a wide variety of complications due to impaired innate immune response, cytokine storm, and thrombo-inflammation. Prolonged use of steroids, diabetes mellitus, and diabetic ketoacidosis (DKA) are some of the factors responsible for the growth of Mucorales in such immunocompromised patients and, thus, can lead to a life-threatening condition referred to as mucormycosis. Therefore, an early diagnosis and cell-based management cosis is the need of the hour to help affected patients overcome this severe condition. In addition, extended exposure to antifungal drugs/therapeutics is found to initiate hormonal and neurological complications. More recently, mesenchymal stem cells (MSCs) have been used to exhibit immunomodulatory function and proven to be beneficial in a clinical cell-based regenerative approach. The immunomodulation ability of MSCs in mucormycosis patient boosts the immunity by the release of chemotactic proteins. MSC-based therapy in mucormycosis along with the combination of short-term antifungal drugs can be utilized as a prospective approach for mucormycosis treatment with promising outcomes. However, preclinical and in mucormyIn mucormycosis, the hyphae of clinical trials are needed to establish the precise mechanism of MSCs in mucormycosis treatment.
COVID-19, Mucormycosis, SARS-CoV-2, immunomodulation, mesenchymal stem cells
Rights and Permissions
Copyright © 2021 Raghav, Ali, Jeong, Gautam, Banday, Mateen, Tripathi, Giri, Agarwal, Singh and Khan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
DOI of Published Version
Raghav A, Ali SG, Jeong GB, Gautam KA, Banday S, Mateen QN, Tripathi P, Giri R, Agarwal S, Singh M, Khan HM. Newer Horizon of Mesenchymal Stem Cell-Based Therapy in the Management of SARS-CoV-2-Associated Mucormycosis: A Safe Hope for Future Medicine. Front Microbiol. 2021 Oct 11;12:738983. doi: 10.3389/fmicb.2021.738983. PMID: 34707590; PMCID: PMC8543035. Link to article on publisher's site
Frontiers in microbiology
Raghav A, Ali SG, Jeong G, Gautam KA, Banday S, Mateen QN, Tripathi P, Giri R, Agarwal S, Singh M, Khan HM. (2021). Newer Horizon of Mesenchymal Stem Cell-Based Therapy in the Management of SARS-CoV-2-Associated Mucormycosis: A Safe Hope for Future Medicine. COVID-19 Publications by UMass Chan Authors. https://doi.org/10.3389/fmicb.2021.738983. Retrieved from https://escholarship.umassmed.edu/covid19/325
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.